David J. MacEwan

David J. MacEwan

Auto-generated profile, based on publicly available information

David J. MacEwan

University of Liverpool Liverpool UK

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2018 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MCMichael J Curtis
Michael J Curtis
SASteve Alexander
Steve Alexander
GCGiuseppe Cirino
Giuseppe Cirino
JDJames R Docherty
James R Docherty
CGChristopher H George
Christopher H George
AAAmrita AHLUWALIA
Amrita AHLUWALIA
This article updates the guidance published in 2015 for authors submitting papers to British Journal of Pharmacology (Curtis et al., 2015) and is intended to provide the rubric for peer review. Thus, it is directed towards authors, reviewers and editors. Explanations for many of the requirements were outlined previously and are not restated here. The new guidelines are intended to replace those published previously. The guidelines have been simplified for ease of understanding by authors, to make it more straightforward for peer reviewers to check compliance and to facilitate the curation of the journal's efforts to improve standards.

26 June 2015 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MCMichael Curtis
Michael Curtis
RBRichard A Bond
Richard A Bond
DSDomenico Spina
Domenico Spina
AAAmrita AHLUWALIA
Amrita AHLUWALIA
SASteve Alexander
Steve Alexander
JMJohn C McGrath
John C McGrath
Linked Editorials: This Editorial is part of a series. To view the other Editorials in this series, visit: http://onlinelibrary.wiley.com/doi/10.1111/bph.12956/abstract; http://onlinelibrary.wiley.com/doi/10.1111/bph.12954/abstract; http://onlinelibrary.wiley.com/doi/10.1111/bph.12955/abstract and http://onlinelibrary.wiley.com/doi/10.1111/bph.13112/abstract

19 January 2018 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SASteve Alexander
Steve Alexander
RRRichard E Roberts
Richard E Roberts
BBBrad R S Broughton
Brad R S Broughton
CSChristopher G Sobey
Christopher G Sobey
CGChristopher H George
Christopher H George
AAAmrita AHLUWALIA
Amrita AHLUWALIA
Click on the article title to read more.

1 June 2002 in Cellular Signalling
Verified
Journal Article
Closed access
DMDavid J. MacEwan
David J. MacEwan

2 February 2002 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
DMDavid J MacEwan
David J MacEwan

20 December 2012 in Blood
Verified
Journal Article
Closed access
PDF file
SRStuart Rushworth
Stuart Rushworth
LZLyubov Zaitseva
Lyubov Zaitseva
MMMegan Y. Murray
Megan Y. Murray
NSNiraj M. Shah
Niraj M. Shah
KBKristian Bowles
Kristian Bowles
DMDavid J. MacEwan
David J. MacEwan
NF-E2–related factor 2 (Nrf2) transcription factor regulates a range of cytoprotective transcriptional responses, preventing further cellular injury by removing biochemical damage and renewing tissue. Here we show that acute myeloid leukemia (AML) cells possess greater constitutive nuclear levels of Nrf2 than normal control CD34+ cells because of an imbalance between mRNA expression levels of Nrf2 and its inhibitor Keap1 but not through their somatic mutation. Elevated Nrf2 was reduced by NF-κB inhibitors. Using promoter assays, ChIP and siRNA knockdown, we demonstrated NF-κB subunits p50 and p65 induce transcription of Nrf2 in AML cells at a specific promoter κB-site and that long-term lentiviral miRNA-knockdown of Nrf2 significantly reduced clonogenicity of AML patient cells and improved their chemotherapeutic responsiveness. Normal physiologic Nrf2 protects cells from damage, but here we have exposed aberrant continuous nuclear activation of Nrf2 in AML that allows cell survival, even against cytotoxic chemotherapeutics. We show for the first time that Nrf2, an important regulator of several biologic processes involved in the progression of cancer, has abnormal NF-κB–driven constitutive expression in AML. Such a mechanism allows for a greater cytoprotective response in human AML cells and encourages their evasion of chemotherapy-induced cytotoxicity, which is necessary for improved clinical outcomes.